FTSE 100 news / Companies and sectors / AstraZeneca / 4 October 2026

AstraZeneca (AZN): news on Sunday 4 October 2026

+3.7 positive

Coverage mostly centred on AstraZeneca's tie-up with Summit Therapeutics and Daiichi Sankyo to test a cancer drug combination, which leans positive. Reports of planned layoffs in Spain offset some of that.

What drove it

Summit cancer collaboration
Spain layoffs
Summit investment

The 4 stories

Each headline's own score, strongest first. Links go to the publisher.

+7.0 AstraZeneca, Daiichi Sankyo & Summit team up to test cancer drug combination Indian Pharma Post
Partnership to test cancer drug combination supports oncology pipeline.
−5.8 AstraZeneca prepares layoffs in Spain despite the strong growth of its business and its hub in Barcelona Demócrata
Planned Spanish layoffs bring negative reputational coverage.
+5.0 Summit Therapeutics (SMMT) Teams Up With AstraZeneca And Daiichi Sankyo, Is It 43% Undervalued? simplywall.st
Collaboration with Summit involving AstraZeneca; mildly positive pipeline news.
+4.2 AstraZeneca agrees to invest in Summit as AstraZeneca stock costs EUR 139.63 AD HOC NEWS
Agrees to invest in Summit; share price quoted.

AstraZeneca: every day · Pharma and healthcare on 4 October 2026 · FTSE 100 overview for the day